Abstract
Post-stroke depression (PSD) significantly impacts patient recovery and quality of life. This study investigates the therapeutic effects of the Yi-nao-jie-yu (YNJY) prescription, a traditional Chinese medicine formula, on PSD. Using a rat model, we demonstrate that YNJY alleviates depressive-like behaviors and hippocampal neuronal damage. The mechanism involves the activation of the Nrf2/GPX4/SLC7A11 signaling pathway, which inhibits ferroptosis—a form of iron-dependent cell death. These findings suggest YNJY is a promising clinical agent for PSD treatment.
Introduction
Post-stroke depression (PSD) is a frequent and debilitating complication of stroke, characterized by anxiety, hopelessness, and a lack of interest in life. While standard antidepressants are available, they often suffer from poor tolerability and significant side effects. Recent research has identified ferroptosis—a programmed cell death pathway driven by iron accumulation and lipid peroxidation—as a key driver of hippocampal damage in depression. This study explores whether the YNJY prescription, known for its neuroprotective properties, can alleviate PSD by targeting this biological "kill switch."
Methods
The researchers employed a multi-level experimental approach combining in vivo animal models and in vitro cellular assays.
Animal Model and Treatment
A PSD rat model was established using sixty male Sprague Dawley (SD) rats. The protocol involved inducing an intracerebral hemorrhage (ICH) followed by four weeks of Chronic Unpredictable Mild Stress (CUMS).
Rats were treated with low or high doses of YNJY. To confirm the mechanism, the Nrf2 inhibitor ML385 was administered to specific groups. Behavioral testing included the Sucrose Preference Test, Tail Suspension Test (TST), Forced Swimming Test (FST), and Open-Field Test (OFT).
Molecular and Cellular Analysis
Transmission Electron Microscopy (TEM) was used to assess mitochondrial damage. Western blotting and qRT-PCR measured protein and gene expression, while specialized kits tracked iron levels, Reactive Oxygen Species (ROS), and Malondialdehyde (MDA). Primary rat hippocampal neurons were also used in vitro to confirm the pathway's necessity.
Results
Behavioral Recovery
YNJY treatment significantly reversed depressive-like behaviors. High-dose YNJY (YNJY-H) increased sucrose preference and decreased immobility time in the TST and FST. In the Open-Field Test, YNJY-treated rats showed a marked increase in rearing and crossing counts compared to the untreated PSD group.
Inhibition of Ferroptosis
Biochemical analysis revealed that YNJY treatment led to a dramatic decrease in iron (Fe), ROS, and MDA levels in the hippocampus, while boosting protective antioxidants like SOD and GSH. TEM imaging confirmed that YNJY prevented mitochondrial shriveling, a hallmark of ferroptosis.
Pathway Activation
Western blots confirmed that YNJY upregulated the expression of Nrf2, GPX4, and SLC7A11 proteins. The "rescue" experiment using the Nrf2 inhibitor ML385 showed that blocking Nrf2 abolished the protective effects of YNJY, proving that the Nrf2/GPX4/SLC7A11 pathway is the primary mechanism of action.
Discussion and Conclusion
This study confirms that ferroptosis is a major driver of hippocampal damage in PSD and that the YNJY prescription effectively mitigates this damage. YNJY is a "poly-pharmacological" intervention consisting of five herbs: Acanthopanax senticosus, Curcuma longa, Fructus Gardeniae sp., Schisandra chinensis, and Bupleurum. This complex mixture provides a robust therapeutic effect by activating the body's master antioxidant regulator, Nrf2.
While these results are promising, future work is needed to identify the specific active compounds within the formula and to conduct clinical trials to confirm safety and efficacy in human patients. Nonetheless, YNJY represents a significant step forward in bridging traditional wisdom with modern molecular biology for the treatment of post-stroke depression.
Summary updated